Cargando…
MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma
Neuroblastoma (NB) is a childhood cancer arising from sympatho-adrenal neural crest cells. MYCN amplification is found in half of high-risk NB patients; however, no available therapies directly target MYCN. Using multi-dimensional metabolic profiling in MYCN expression systems and primary patient tu...
Autores principales: | Tao, Ling, Mohammad, Mahmoud A., Milazzo, Giorgio, Moreno-Smith, Myrthala, Patel, Tajhal D., Zorman, Barry, Badachhape, Andrew, Hernandez, Blanca E., Wolf, Amber B., Zeng, Zihua, Foster, Jennifer H., Aloisi, Sara, Sumazin, Pavel, Zu, Youli, Hicks, John, Ghaghada, Ketan B., Putluri, Nagireddy, Perini, Giovanni, Coarfa, Cristian, Barbieri, Eveline |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240069/ https://www.ncbi.nlm.nih.gov/pubmed/35764645 http://dx.doi.org/10.1038/s41467-022-31331-2 |
Ejemplares similares
-
CHAF1A Blocks Neuronal Differentiation and Promotes Neuroblastoma Oncogenesis via Metabolic Reprogramming
por: Tao, Ling, et al.
Publicado: (2021) -
Correction: MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma
por: Agarwal, Saurabh, et al.
Publicado: (2018) -
MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma
por: Agarwal, Saurabh, et al.
Publicado: (2018) -
Restoration of the molecular clock is tumor suppressive in neuroblastoma
por: Moreno-Smith, Myrthala, et al.
Publicado: (2021) -
MYCN Amplification, along with Wild-Type RB1 Expression, Enhances CDK4/6 Inhibitors’ Efficacy in Neuroblastoma Cells
por: De Rosa, Piergiuseppe, et al.
Publicado: (2023)